Wuxi Apptec (603259:SSE) written Q&A, November 11, 2025 transcript

Transcript, summary, guidance, and what analysts pressed on from the Wuxi Apptec call on November 11, 2025.

FreeSee Wuxi Apptec's financials in GloomOpen in browser →Jump to the transcript
Held
November 11, 2025
Tone
Mildly positive0.35
Words
2,522
Continuing-operations revenue growth
22.5% year-on-yearfirst three quarters
Adjusted non-IFRS net profit growth
43.4% year-on-yearfirst three quarters
Continuing-operations orders in hand
59.88 billion yuanup 41.2% year-on-year; record high
Peptide capacity completed
more than 100,000 literscompleted in Q3 ahead of schedule
Peptide capacity built this year
more than 60,000 litresmostly for late-stage clinical projects
Peptide capacity full operation
end of 26 years and the beginning of 27 yearsmanagement’s wording
Cash dividend ratio
30%since listing

Summary

Management framed durable CRDMO demand and capacity expansion as the growth engine, while emphasizing policy uncertainty and declining to quantify near-term peptide ramp or pricing effects.

  • More than 100,000 liters of peptide capacity was completed ahead of schedule in Q3, but validation and customer audits precede ramp-up.
  • The company said TIDES backlog reflects customer delivery expectations over the next 18 months, partially incorporating new capacity planned for next year.
  • 30%Management reiterated its 30% cash-dividend policy but did not commit to a higher shareholder payout next year.

Guidance

  • This year’s rapid growth in net profit attributable to the parent is expected to be returned to shareholders through cash dividends.

What analysts pressed on

  • 01U.S. biosafety legislation: WuXi is not named in current NDAA versions, but the legislative process remains complex and evolving.
  • 02Peptide backlog deceleration: management cited the 18-month delivery horizon but did not explain the slowdown or quantify backlog additions.
  • 03Drug-price cuts and CXO pricing: management stressed efficiency and quality alongside cost, but did not say whether customers are lowering contract prices.
  • 04Shareholder reduction and stock-price support: management called the reduction shareholders’ own decision and offered no specific share-price support plan.
  • 05AI drug discovery: management described industry adoption as early-stage and said AI may improve efficiency, without quantifying impact on discovery demand.

Notable disclosures

  • More than 60,000 liters of polypeptide capacity was built this year, mainly for potential late-stage clinical projects.
  • The new peptide capacity requires production verification, audits and ramp-up before full operation, rather than an immediate production contribution.
  • Management said the TIDES backlog covers expected deliveries over the next 18 months, partially including next year’s new capacity.
  • 30%The CFO reaffirmed an industry-leading 30% cash-dividend ratio, but gave no commitment to increase next year’s payout.

Risks raised

  • The U.S. NDAA process remains complex and evolving, with further discussion and possible amendments before final passage in 2026.
  • Management did not clarify whether drug-price reductions could pressure prices paid to CXO providers.
  • TIDES backlog growth was reported by the investor as slowing to 17%; management did not explain the deceleration.

Tone: Mildly positive 0.35

Management expressed confidence in CRDMO demand and long-term growth, but capacity ramp timing, legislative uncertainty and evasive answers temper the positive tone.

Who spoke

Company

  • Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC
  • Shi MingChief Financial Officer, WUXI APPTEC
  • Han MinBoard Secretary, WUXI APPTEC
  • Yang QingExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

Full transcript

Analyst questions are marked with a bar. Timestamps are into the recording.

Prepared remarks

ModeratorSSE Roadshow Center

Hello, distinguished guests, investors, and online viewers! Welcome to the WuXi AppTec 2025 Third Quarter Results Presentation. This event is hosted by WUXI APPTEC, with online platform support provided by SSE Info Network Co., Ltd. Thank you for your interest and participation. On October 27, WUXI APPTEC published its 2025 Third Quarter Report. Investors may visit the Shanghai Stock Exchange website (https://www.sse.com.cn/) or this platform (https://roadshow.sseinfo.com/) to view the relevant announcements.

To help investors gain a more comprehensive and in-depth understanding of the company's operating results and financial position for the third quarter of 2025, the company has decided to hold the WuXi AppTec 2025 Third Quarter Results Presentation. At today's event, key members of WUXI APPTEC's management are joining us at the SSE Roadshow Center to communicate and exchange views with investors. Everyone is welcome to participate actively.

Questions and answers

Investor

May I ask: Has the U.S. Biosecure Act had a major impact on the company?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company said: We have been paying attention to new legislative proposals in the United States, and so far this year there has been no separate legislative proposal on biosafety law. We understand that during the recent Senate review of the National Defense Authorization Act for Fiscal Year 2026 (NDAA), an amendment related to biotechnology security was proposed for inclusion in the Senate version. WuXi AppTec is not mentioned in this amendment or in the current Senate or House versions of the NDAA.

At present, the whole NDAA legislative process is still complex and evolving. There will be further discussions, clarifications and possible amendments in Congress before the final passage of the NDAA in 2026. We will continue to closely monitor legislative developments and continue to communicate with relevant policy makers to ensure that they better understand our work for patients around the world. The company's CRDMO business model closely follows customer needs and continuously guarantees the company's long-term development.

In the first three quarters, the company's revenue from continuing operations increased by 22.5% year-on-year, the adjusted non-IFRS net profit attributable to the parent company increased by 43.4% year-on-year, and the orders in hand of continuing operations reached 59.88 billion yuan, a record high, an increase of 41.2% year-on-year.

Investor

Dear Mr. Minzhang, Hello! The company's third-quarter report clearly states that by the end of the third quarter, the company had already completed construction of 100,000 liters of peptide capacity ahead of schedule. I would like to ask: 1. The third-quarter report disclosed that TIDES orders on hand grew by 17%. This growth rate was clearly much slower than last quarter. Mr. Minzhang, could you disclose the reason for the significant slowdown? 2. Peptide capacity reached 100,000 liters in the third quarter.

Mr. Minzhang, how much of the newly added 60,000 liters of capacity is expected to ramp up in the fourth quarter (how much capacity will have completed ramp-up by the end of the fourth quarter)? Will it ramp up month by month? 3. Apart from the TIDES business, what are management's expectations for the company's long-term growth over the next five years? After TIDES, will the company face a loss of growth momentum? What will the new growth drivers be over the next few years?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that TIDES orders in hand are based on the customer's expected delivery demand for the next 18 months, which has partially covered the gradual release of this year's new production capacity next year. At the same time, more than 60000 litres of polypeptide production capacity have been built this year, mostly to prepare for more late-stage clinical projects, enabling more potential pipelines and new drugs to come out in the future.

In the third quarter of this year, we completed the construction of more than 100,000 liters of polypeptide production capacity ahead of schedule. The new production capacity needs time to complete the verification of production, related audits and climbing. It is expected that these new production capacity will gradually achieve full capacity operation by the end of 26 years and the beginning of 27 years.

The company's unique integrated, end-to-end CRDMO business model helps us to enhance the ability to continuously drain high-quality molecules, as well as the predictability of the demand for early capacity construction, so as to better help customers and continuously meet the emerging needs of new drug research and development. In the future, the company will continue to focus on the core strategy of CRDMO, accelerate the launch of global capabilities and production capacity, and improve the efficiency of production and operation.

The growth of the company in the past 25 years has proved to you that the company upholds the great vision of "making the world free from difficult medicines and diseases", and uses efficient and high-quality services to empower global customers and benefit global patients. At the same time, the company's business strategy and strong execution ability, no matter how the external environment changes, the company is confident and confident that it will continue to develop in the past and in the future.

Create more value for the industry, customers, patients, employees and shareholders.

Investor

Dear Mr. Min Zhang, Hello! Recently, President Trump of the United States is engaged in negotiations with major pharmaceutical companies in Europe and the United States to reduce the prices of American medications. For example, the prices of well-known weight loss medications have been significantly lowered. The market believes that reducing medication prices will encourage innovative pharmaceutical companies to optimize efficiency and reduce costs, thereby promoting a rapid increase in the penetration of outsourced pharmaceutical research and development services.

The significant reduction in the prices of weight loss medications is expected to lead to a substantial increase in sales, which will undoubtedly have a positive impact on the growth of the company's TIDES business. Is Mr. Min Zhang in agreement with this perspective as well?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that it has always been the goal of the whole industry to make more and better drugs, more breakthrough therapies, and more patients at a price that more people can pay. As a trusted partner and important contributor to the global pharmaceutical and life sciences industry, the company has been working hard to this end.

The company will continue to focus on the core strategy of CRDMO, accelerate the launch of global capabilities and production capacity, continuously improve the efficiency of production and operation, create greater value for customers and benefit patients around the world.

Investor

Could you please clarify whether the reduction in drug prices in the United States is causing pharmaceutical companies to lower the prices they pay to CXO contract manufacturers?

Shi MingChief Financial Officer, WUXI APPTEC

In response to your question, the company believes that it has always been the goal of the whole industry to make more and better drugs, more breakthrough therapies, and more patients at a price that more people can pay. As a trusted partner and important contributor to the global pharmaceutical and life sciences industry, the company has been working hard to this end. At the same time, in the process of new drug research and development, customers not only pay attention to cost, but also to efficiency and quality.

Our unique CRDMO business model and constantly improving operational efficiency enable us to provide customers with solutions and high-quality services. The company will continue to focus on the core strategy of CRDMO, accelerate the launch of global capabilities and production capacity, continuously improve the efficiency of production and operation, create greater value for customers and benefit patients around the world.

Investor

Considering that this year's dividend plus repurchase is nearly 7 billion, and this year's sale of assets is expected to have more than 5 billion earnings, according to the dividend ratio of about 30% in previous years, will the part given to shareholders next year be higher?

Shi MingChief Financial Officer, WUXI APPTEC

In response to your question, the company believes that since listing, the company has been adhering to the industry-leading 30% cash dividend ratio while continuously investing in capacity and scale construction. This year, it is expected that the rapid growth of net profit attributable to the parent company will also be fed back to shareholders in the form of cash dividends.

Investor

Why, after the strongest quarterly report in history, was there an announcement about the actual controller's large-scale increase in holdings? What is the company's position on maintaining market capitalization?

Han MinBoard Secretary, WUXI APPTEC

In response to your question, the company believes that the reduction is a decision made by shareholders based on their own needs and plans. The Company shall disclose relevant information in a timely manner in accordance with the Listing Rules. Up to now, in the seven years since its listing, the company has returned 20 billion yuan to investors through cash dividends and share repurchase and cancellation, exceeding 40% of the company's cumulative net profit in the past seven years, ranking first among all listed companies.

This reflects that the company continues to create value for shareholders and attach importance to shareholder returns while expanding its scale and building its capabilities to meet customer needs. In the future, the company will continue to provide customers with the ultimate service, benefit patients around the world, and have full confidence in our unique integrated CRDMO business model and the company's sustainable development in the future. We are confident and confident that we will continue to create more value for investors who believe in the company's excellent business development and management execution capabilities.

Investor

Mr. Yang, what is the potential impact of the company's sale of domestic clinical CRO business on the CDRMO strategy of the company's whole industry chain layout?

Yang QingExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the company continues to focus on its unique CRDMO model, focusing on drug discovery, laboratory testing and process development and production services, and enhancing business synergies between research (R), development (D) and production (M). The company will continue to accelerate global capacity building and capacity delivery, so as to better serve global customers, benefit patients, and realize the great vision of "no difficult medicine, no difficult disease" as soon as possible.

Investor

I would like to ask Mr. Minzhang, one of your company's major customers, Eli Lilly and Nvidia, jointly build AI drug research and development, all of which are discovering molecules that cannot be discovered by human beings alone through AI. What is the trend impact of pharmaceutical companies joining AI drug research and development on your company's drug discovery R business?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the whole industry is in the early stage of exploring how to use AI to accelerate the development of innovative drugs, and we also see many customers trying. We believe that AI, as an innovative tool, can help the whole industry improve efficiency and speed, and may open up more new space for new drug research and development in the future. We will also follow the trend and better provide our customers with the ultimate service.

The company's strategy has always been to make good use of HI and AI to help us continuously improve our operational efficiency, enhance our insight into the industry and predictability of our business, so as to better serve our customers and patients.

Investor

How does the company respond to and make decisions on the previous reduction announcement?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that up to now, in the seven years since listing, the company has returned 20 billion yuan to investors through cash dividends and repurchase and cancellation of shares, exceeding 40% of the company's cumulative net profit in the past seven years, ranking first among all listed companies. This reflects that the company continues to create value for shareholders and attach importance to shareholder returns while expanding its scale and building its capabilities to meet customer needs.

In the future, the company will continue to provide customers with the ultimate service, benefit patients around the world, and have full confidence in our unique integrated CRDMO business model and the company's sustainable development in the future. We are confident and confident that we will continue to create more value for investors who believe in the company's excellent business development and management execution capabilities.

Investor

Why should the actual controllers reduce their holdings on a large scale after the release of the company's strongest three-quarter report? Is it the need for shareholders to cash out or to introduce more strategic investors at home and abroad. Does the company have a plan for the next step to maintain the stock price for the resulting decline in the stock price?

Chen MinzhangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

In response to your question, the company believes that the reduction is a decision made by shareholders based on their own needs and plans. The Company shall disclose relevant information in a timely manner in accordance with the Listing Rules. Up to now, in the seven years since its listing, the company has returned 20 billion yuan to investors through cash dividends and share repurchase and cancellation, exceeding 40% of the company's cumulative net profit in the past seven years, ranking first among all listed companies.

This reflects that the company continues to create value for shareholders and attach importance to shareholder returns while expanding its scale and building its capabilities to meet customer needs. In the future, the company will continue to provide customers with the ultimate service, benefit patients around the world, and have full confidence in our unique integrated CRDMO business model and the company's sustainable development in the future. We are confident and confident that we will continue to create more value for investors who believe in the company's excellent business development and management execution capabilities.

Han MinBoard Secretary, WUXI APPTEC

Due to time constraints, the results presentation of WuXi AppTec for the third quarter of 2025 has ended. I am very pleased to discuss and communicate with you on the company's industry situation, business situation and other aspects. I also sincerely thank all investors for their warm and friendly exchanges and their continuous attention and ardent expectations for WuXi AppTec! After the meeting, investors are welcome to further communicate with us through diversified ways such as investor relations telephone, e-mail and SSE e-interaction.

ModeratorSSE Roadshow Center

Dear investors and netizens, the performance presentation of WuXi AppTec for the third quarter of 2025 is drawing to a close. We invite guests from listed companies to make concluding remarks.

ModeratorSSE Roadshow Center

This is the successful conclusion of the performance presentation of WuXi AppTec for the third quarter of 2025. Thank you for the active participation of investors and netizens. If you have further questions, you can keep communicating with the company through the e interactive platform of Shanghai Stock Exchange. Thank you!

Other Wuxi Apptec earnings calls

  • Q2 2026 earnings call

    Management framed growth as increasingly supported by later-stage molecule progression, rising capacity utilization and operating efficiency.

    Aug 28, 2026Confident0.82
  • written Q&A, August 27, 2026

    Management framed the raised outlook as demand-led pipeline conversion, while emphasizing execution, capacity readiness and resilience amid geopolitical and currency headwinds.

    Aug 28, 2026Positive0.48
  • written Q&A, April 12, 2026

    Management framed growth around CRDMO capacity expansion and operational efficiency, while offering little quantified detail on pricing, capital allocation or customer concentration.

    Apr 13, 2026Mildly positive0.35
  • written Q&A, August 28, 2025

    Management framed the call around strong demand and execution, raising its full-year outlook while balancing shareholder returns with global capacity investment.

    Aug 29, 2025Confident0.75

All Wuxi Apptec transcripts

About this transcript

The call was held in another language and translated. The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.